Sun Pharmaceutical Industries Limited — Updates, 03-06-2025: Press Release

Sun Pharma announced that Phase 2 trials for SCD-044 in moderate to severe psoriasis and atopic dermatitis missed primary efficacy goals. No major safety issues were observed, but the company is halting further development of SCD-044. This affects their specialty inflammation portfolio, though the drug confirmed target engagement. Sun Pharma will assess future options for this asset while maintaining focus on its specialty generics and global dermatology businesses.